Active	Status	Sponsor type	Region	Phase	Filter
17 Active 1 Inactive 18 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kolevska, Tatjana
KEYSTONE 1, NCT06297486: Study of a Gene Therapy Treatment for Hemophilia A	Recruiting	3	85	US	SPK-8011, AAV-Spark200-BDD-hFVIII, Dirloctocogene samoparvovec	Spark Therapeutics, Inc.	Hemophilia A	05/27	09/35
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI	Recruiting	3	1100	Canada, US	Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20	SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP	Multiple Myeloma	07/29	07/40
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease	Recruiting	2/3	1912	Canada, US	Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month	NRG Oncology, Natera, Inc., National Cancer Institute (NCI)	Stage III Colon Cancer	03/29	03/30